Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
Medpage Today on MSN3mon
New CAR T-Cell Therapy Approved for LeukemiaOf note, unlike other CAR T-cell therapies, the CD19-directed genetically modified ... have relapsed or refractory ALL after ...
CD19, a B-cell surface protein ... antibody affinity measurement and detection of anti-CD19 CAR expression. The high activity of such proteins has been confirmed by ELISA, SPR and flow cytometry ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Markers associated to B (CD19), NK (CD16/56) or myelomonocytic (CD13, CD33 and CD63) lineage were negative. CUTLL1 cells showed ... established mouse lines still require high levels of activated ...
The high-affinity CD19 proteins from ACROBiosystems exhibit the potential to effectively detect the anti-CD19 CAR expression on the surface of transduced T cells. These proteins have been ...
Zacks.com on MSN6mon
Bristol Myers' (BMY) Breyanzi Label Expansion Application ValidatedBristol Myers Squibb BMY announced that the European Medicines Agency (“EMA”) has validated its type II variation application ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback